Carlos Nolasco, MD, FACP, AHSCP-CHS
@carlosnolascomd.com
GIM 🫀 #Hypertension Specialist 🩺 👨⚕️ (AHSCP-CHS) | 🇸🇻 trained | Chicago✶ trained | Lots of 👨💻 | Posts are my own.
Pinned
Reposted by Carlos Nolasco, MD, FACP, AHSCP-CHS
In a meta-analysis of 17,801 patients with myocardial infarction and preserved LVEF (≥50%), beta-blockers did not reduce death, MI, or heart failure over a median 3.6 years of follow-up. Full results: nej.md/43U5Ppo
#AHA25
#AHA25
November 9, 2025 at 4:14 PM
In a meta-analysis of 17,801 patients with myocardial infarction and preserved LVEF (≥50%), beta-blockers did not reduce death, MI, or heart failure over a median 3.6 years of follow-up. Full results: nej.md/43U5Ppo
#AHA25
#AHA25
Reposted by Carlos Nolasco, MD, FACP, AHSCP-CHS
In rural South Africa, home-based hypertension care — delivered by community health workers and supported by remote nurses — led to a lower mean systolic blood pressure than clinic-based care. Full IMPACT-BP trial results and Research Summary: nej.md/4lHJ4ek
#MedSky #CardioSky
#MedSky #CardioSky
October 8, 2025 at 1:03 PM
In rural South Africa, home-based hypertension care — delivered by community health workers and supported by remote nurses — led to a lower mean systolic blood pressure than clinic-based care. Full IMPACT-BP trial results and Research Summary: nej.md/4lHJ4ek
#MedSky #CardioSky
#MedSky #CardioSky
Reposted by Carlos Nolasco, MD, FACP, AHSCP-CHS
Fwd: Fwd: “I hope this email finds you well”
October 7, 2025 at 8:37 AM
Fwd: Fwd: “I hope this email finds you well”
Reposted by Carlos Nolasco, MD, FACP, AHSCP-CHS
🩺 Knowledge is power. 🫀 On this #WorldHeartDay, empower your patients to take control of their heart health with #CardioSmart tools like this high #bloodpressure infographic.
🔗 Explore more: https://bit.ly/46I6k6F
#DontMissABeat #WorldHeartDay
🔗 Explore more: https://bit.ly/46I6k6F
#DontMissABeat #WorldHeartDay
September 29, 2025 at 5:49 PM
🩺 Knowledge is power. 🫀 On this #WorldHeartDay, empower your patients to take control of their heart health with #CardioSmart tools like this high #bloodpressure infographic.
🔗 Explore more: https://bit.ly/46I6k6F
#DontMissABeat #WorldHeartDay
🔗 Explore more: https://bit.ly/46I6k6F
#DontMissABeat #WorldHeartDay
Reposted by Carlos Nolasco, MD, FACP, AHSCP-CHS
Subclinical primary aldosteronism is an under-recognized driver of cardiovascular risk. Could it be a new target for CV prevention? Read our Circulation editorial —>
September 29, 2025 at 7:03 PM
Subclinical primary aldosteronism is an under-recognized driver of cardiovascular risk. Could it be a new target for CV prevention? Read our Circulation editorial —>
Reposted by Carlos Nolasco, MD, FACP, AHSCP-CHS
Superficial vein thrombosis (SuVT) is characterized by thrombus in the superficial veins, typically in the lower or upper extremities.
This Review summarizes the diagnosis and treatment of SuVT.
ja.ma/46CnGlh
This Review summarizes the diagnosis and treatment of SuVT.
ja.ma/46CnGlh
September 28, 2025 at 2:00 PM
Superficial vein thrombosis (SuVT) is characterized by thrombus in the superficial veins, typically in the lower or upper extremities.
This Review summarizes the diagnosis and treatment of SuVT.
ja.ma/46CnGlh
This Review summarizes the diagnosis and treatment of SuVT.
ja.ma/46CnGlh
Reposted by Carlos Nolasco, MD, FACP, AHSCP-CHS
*At grandson's birthday*
Me: ...so that's why you should get your kid enrolled in swim lessons.
Son: MOM ARE YOU TELLING DROWNING STORIES TO THE GUESTS AT MY SON'S BIRTHDAY PARTY?
Me:
Son:
Me: I can change.
Me: ...so that's why you should get your kid enrolled in swim lessons.
Son: MOM ARE YOU TELLING DROWNING STORIES TO THE GUESTS AT MY SON'S BIRTHDAY PARTY?
Me:
Son:
Me: I can change.
September 28, 2025 at 1:06 AM
*At grandson's birthday*
Me: ...so that's why you should get your kid enrolled in swim lessons.
Son: MOM ARE YOU TELLING DROWNING STORIES TO THE GUESTS AT MY SON'S BIRTHDAY PARTY?
Me:
Son:
Me: I can change.
Me: ...so that's why you should get your kid enrolled in swim lessons.
Son: MOM ARE YOU TELLING DROWNING STORIES TO THE GUESTS AT MY SON'S BIRTHDAY PARTY?
Me:
Son:
Me: I can change.
Reposted by Carlos Nolasco, MD, FACP, AHSCP-CHS
CDC to recommend looking only one way before crossing street
September 19, 2025 at 7:26 AM
CDC to recommend looking only one way before crossing street
Reposted by Carlos Nolasco, MD, FACP, AHSCP-CHS
#TWDFNR: Primary/essential hypertension? Or...primary aldosteronism? JHM Digital Media Fellow Eric Burnett discusses why we might not be screening our patients with elevated blood pressures, and why we should!
https://bit.ly/4pymLv7
#VisualAbstract: Sophie Sun
📹: @Eric
https://bit.ly/4pymLv7
#VisualAbstract: Sophie Sun
📹: @Eric
September 25, 2025 at 4:27 PM
#TWDFNR: Primary/essential hypertension? Or...primary aldosteronism? JHM Digital Media Fellow Eric Burnett discusses why we might not be screening our patients with elevated blood pressures, and why we should!
https://bit.ly/4pymLv7
#VisualAbstract: Sophie Sun
📹: @Eric
https://bit.ly/4pymLv7
#VisualAbstract: Sophie Sun
📹: @Eric
Reposted by Carlos Nolasco, MD, FACP, AHSCP-CHS
📢 New in #JACC: ACC/AHA methodology statements on:
🔹 Core Principles & Development
🔹 Cost/Value (update)
🔹 FDA Processes
Together with Circulation, they provide the framework to keep guidelines rigorous, transparent & responsive.
🔗 Explore the statements: https://bit.ly/3IE4EDc #CardioSky #MedSky
🔹 Core Principles & Development
🔹 Cost/Value (update)
🔹 FDA Processes
Together with Circulation, they provide the framework to keep guidelines rigorous, transparent & responsive.
🔗 Explore the statements: https://bit.ly/3IE4EDc #CardioSky #MedSky
September 25, 2025 at 7:00 PM
📢 New in #JACC: ACC/AHA methodology statements on:
🔹 Core Principles & Development
🔹 Cost/Value (update)
🔹 FDA Processes
Together with Circulation, they provide the framework to keep guidelines rigorous, transparent & responsive.
🔗 Explore the statements: https://bit.ly/3IE4EDc #CardioSky #MedSky
🔹 Core Principles & Development
🔹 Cost/Value (update)
🔹 FDA Processes
Together with Circulation, they provide the framework to keep guidelines rigorous, transparent & responsive.
🔗 Explore the statements: https://bit.ly/3IE4EDc #CardioSky #MedSky
Reposted by Carlos Nolasco, MD, FACP, AHSCP-CHS
Early identification is 🔑 for FH. Use #CardioSmart’s FH infographic to explain types of FH & support patient conversations. To celebrate #FHAwarenessDay, CardioSmart is offering free handouts & posters for a limited ⏰.
Learn more & order now ➡️ https://bit.ly/4gKKlRk #KnowFH #CardioSky #MedSky
Learn more & order now ➡️ https://bit.ly/4gKKlRk #KnowFH #CardioSky #MedSky
September 24, 2025 at 5:07 PM
Early identification is 🔑 for FH. Use #CardioSmart’s FH infographic to explain types of FH & support patient conversations. To celebrate #FHAwarenessDay, CardioSmart is offering free handouts & posters for a limited ⏰.
Learn more & order now ➡️ https://bit.ly/4gKKlRk #KnowFH #CardioSky #MedSky
Learn more & order now ➡️ https://bit.ly/4gKKlRk #KnowFH #CardioSky #MedSky
Reposted by Carlos Nolasco, MD, FACP, AHSCP-CHS
Help your patients better understand #AFib with #CardioSmart’s Spanish infographic! 👇
CardioSmart offers infographics and decision aids in multiple languages to support patient–clinician conversations. Explore the resources: https://bit.ly/4pxad6Y
#AFibAwarenessMonth #ACCLATAM #CardioSky #MedSky
CardioSmart offers infographics and decision aids in multiple languages to support patient–clinician conversations. Explore the resources: https://bit.ly/4pxad6Y
#AFibAwarenessMonth #ACCLATAM #CardioSky #MedSky
September 20, 2025 at 8:40 PM
Help your patients better understand #AFib with #CardioSmart’s Spanish infographic! 👇
CardioSmart offers infographics and decision aids in multiple languages to support patient–clinician conversations. Explore the resources: https://bit.ly/4pxad6Y
#AFibAwarenessMonth #ACCLATAM #CardioSky #MedSky
CardioSmart offers infographics and decision aids in multiple languages to support patient–clinician conversations. Explore the resources: https://bit.ly/4pxad6Y
#AFibAwarenessMonth #ACCLATAM #CardioSky #MedSky
Reposted by Carlos Nolasco, MD, FACP, AHSCP-CHS
You say "happy birthday," I say "Another year older, another loss of 0.9 ml/min of eGFR"
September 19, 2025 at 3:41 PM
You say "happy birthday," I say "Another year older, another loss of 0.9 ml/min of eGFR"
Reposted by Carlos Nolasco, MD, FACP, AHSCP-CHS
Some information (still not primary data, more like marketing speak) about the Apple Hypertension detection.
>2,000 adults wore the watch ~12 hours/day for a month and took BID cuff BP; The watch was “as accurate as the cuff” for detecting signs of HTN what ever that is
time.com/7316725/appl...
>2,000 adults wore the watch ~12 hours/day for a month and took BID cuff BP; The watch was “as accurate as the cuff” for detecting signs of HTN what ever that is
time.com/7316725/appl...
time.com
September 13, 2025 at 1:52 PM
Some information (still not primary data, more like marketing speak) about the Apple Hypertension detection.
>2,000 adults wore the watch ~12 hours/day for a month and took BID cuff BP; The watch was “as accurate as the cuff” for detecting signs of HTN what ever that is
time.com/7316725/appl...
>2,000 adults wore the watch ~12 hours/day for a month and took BID cuff BP; The watch was “as accurate as the cuff” for detecting signs of HTN what ever that is
time.com/7316725/appl...
Reposted by Carlos Nolasco, MD, FACP, AHSCP-CHS
ACOG reaffirms that acetaminophen is safe for managing pain and fever during pregnancy. No reputable studies support suggestions like those in HHS’s recent announcement linking acetaminophen use in pregnancy to autism; in fact, high-quality studies show no such risk. https://bit.ly/47Wxc59
September 22, 2025 at 9:24 PM
ACOG reaffirms that acetaminophen is safe for managing pain and fever during pregnancy. No reputable studies support suggestions like those in HHS’s recent announcement linking acetaminophen use in pregnancy to autism; in fact, high-quality studies show no such risk. https://bit.ly/47Wxc59
Reposted by Carlos Nolasco, MD, FACP, AHSCP-CHS
New in #ASNJASN and at #Hypertension25: In a randomized, double-blind, placebo-controlled trial, Baxdrostat reduced systolic blood pressure in patients with CKD and uncontrolled hypertension. Read more about its safety and efficacy in patients with CKD here: kidney.pub/JASN0849
September 6, 2025 at 2:00 PM
New in #ASNJASN and at #Hypertension25: In a randomized, double-blind, placebo-controlled trial, Baxdrostat reduced systolic blood pressure in patients with CKD and uncontrolled hypertension. Read more about its safety and efficacy in patients with CKD here: kidney.pub/JASN0849
Reposted by Carlos Nolasco, MD, FACP, AHSCP-CHS
In patients with localized colorectal cancer and PIK3CA hotspot mutations in exon 9 or 20, daily low-dose aspirin resulted in a significantly lower recurrence rate than placebo. Full ALASCCA phase 3 trial results and Research Summary: nej.md/4mpKXNp
#MedSky #Oncology
#MedSky #Oncology
September 21, 2025 at 1:00 PM
In patients with localized colorectal cancer and PIK3CA hotspot mutations in exon 9 or 20, daily low-dose aspirin resulted in a significantly lower recurrence rate than placebo. Full ALASCCA phase 3 trial results and Research Summary: nej.md/4mpKXNp
#MedSky #Oncology
#MedSky #Oncology
Reposted by Carlos Nolasco, MD, FACP, AHSCP-CHS
It’s a beautiful day to go get vaccinated!
September 16, 2025 at 3:46 PM
It’s a beautiful day to go get vaccinated!
Reposted by Carlos Nolasco, MD, FACP, AHSCP-CHS
T1h
Next up – Secondary HTN. The guideline provides a thorough table including 15 causes of secondary HTN with indications for additional testing and diagnostic screening tests for each.
#NephJC
Next up – Secondary HTN. The guideline provides a thorough table including 15 causes of secondary HTN with indications for additional testing and diagnostic screening tests for each.
#NephJC
September 17, 2025 at 1:21 AM
T1h
Next up – Secondary HTN. The guideline provides a thorough table including 15 causes of secondary HTN with indications for additional testing and diagnostic screening tests for each.
#NephJC
Next up – Secondary HTN. The guideline provides a thorough table including 15 causes of secondary HTN with indications for additional testing and diagnostic screening tests for each.
#NephJC
Reposted by Carlos Nolasco, MD, FACP, AHSCP-CHS
T4g
7️⃣Pregnancy thresholds updated - Treat chronic HTN in pregnancy to <140/90 and acute severe HTN ≥160/110 within 30–60 min (COR I, LOE B-R).
📝Are you routinely consulted for hypertension in pregnancy? #NephJC
7️⃣Pregnancy thresholds updated - Treat chronic HTN in pregnancy to <140/90 and acute severe HTN ≥160/110 within 30–60 min (COR I, LOE B-R).
📝Are you routinely consulted for hypertension in pregnancy? #NephJC
September 17, 2025 at 1:46 AM
T4g
7️⃣Pregnancy thresholds updated - Treat chronic HTN in pregnancy to <140/90 and acute severe HTN ≥160/110 within 30–60 min (COR I, LOE B-R).
📝Are you routinely consulted for hypertension in pregnancy? #NephJC
7️⃣Pregnancy thresholds updated - Treat chronic HTN in pregnancy to <140/90 and acute severe HTN ≥160/110 within 30–60 min (COR I, LOE B-R).
📝Are you routinely consulted for hypertension in pregnancy? #NephJC
Reposted by Carlos Nolasco, MD, FACP, AHSCP-CHS
T4e
5️⃣Primary aldosteronism screening – screen all adults with resistant HTN regardless of potassium level (COR I, LOE B-NR). Continue most antihypertensives except MRA before testing (COR I, LOE C-EO).
📝Is screening worthwhile or should we just be using MRAs earlier? #NephJC
5️⃣Primary aldosteronism screening – screen all adults with resistant HTN regardless of potassium level (COR I, LOE B-NR). Continue most antihypertensives except MRA before testing (COR I, LOE C-EO).
📝Is screening worthwhile or should we just be using MRAs earlier? #NephJC
September 17, 2025 at 1:44 AM
T4e
5️⃣Primary aldosteronism screening – screen all adults with resistant HTN regardless of potassium level (COR I, LOE B-NR). Continue most antihypertensives except MRA before testing (COR I, LOE C-EO).
📝Is screening worthwhile or should we just be using MRAs earlier? #NephJC
5️⃣Primary aldosteronism screening – screen all adults with resistant HTN regardless of potassium level (COR I, LOE B-NR). Continue most antihypertensives except MRA before testing (COR I, LOE C-EO).
📝Is screening worthwhile or should we just be using MRAs earlier? #NephJC
Reposted by Carlos Nolasco, MD, FACP, AHSCP-CHS
T4i
9️⃣Cognitive protection🧠 - treat to SBP <130 to prevent mild cognitive impairment/dementia (COR I, LOE B-R).
📝Do you think BP control has a significant role in dementia? #NephJC
9️⃣Cognitive protection🧠 - treat to SBP <130 to prevent mild cognitive impairment/dementia (COR I, LOE B-R).
📝Do you think BP control has a significant role in dementia? #NephJC
September 17, 2025 at 1:48 AM
T4i
9️⃣Cognitive protection🧠 - treat to SBP <130 to prevent mild cognitive impairment/dementia (COR I, LOE B-R).
📝Do you think BP control has a significant role in dementia? #NephJC
9️⃣Cognitive protection🧠 - treat to SBP <130 to prevent mild cognitive impairment/dementia (COR I, LOE B-R).
📝Do you think BP control has a significant role in dementia? #NephJC
Reposted by Carlos Nolasco, MD, FACP, AHSCP-CHS
T3a
1️⃣3️⃣Terminology change – Hypertensive Urgency (BP > 180/120 without target organ damage) is now referred to as Severe HTN. No need for parenteral therapy, best to treat in the outpatient setting.
📝What’s in a name (renal, nephro, kidney)? #NephJC
1️⃣3️⃣Terminology change – Hypertensive Urgency (BP > 180/120 without target organ damage) is now referred to as Severe HTN. No need for parenteral therapy, best to treat in the outpatient setting.
📝What’s in a name (renal, nephro, kidney)? #NephJC
September 17, 2025 at 1:52 AM
T3a
1️⃣3️⃣Terminology change – Hypertensive Urgency (BP > 180/120 without target organ damage) is now referred to as Severe HTN. No need for parenteral therapy, best to treat in the outpatient setting.
📝What’s in a name (renal, nephro, kidney)? #NephJC
1️⃣3️⃣Terminology change – Hypertensive Urgency (BP > 180/120 without target organ damage) is now referred to as Severe HTN. No need for parenteral therapy, best to treat in the outpatient setting.
📝What’s in a name (renal, nephro, kidney)? #NephJC
Reposted by Carlos Nolasco, MD, FACP, AHSCP-CHS
September 17, 2025 at 1:42 AM
Reposted by Carlos Nolasco, MD, FACP, AHSCP-CHS
T4b
2️⃣Risk-based treatment threshold – Use PREVENT 10-yr CVD risk ≥7.5% to guide drug initiation at ≥130/80; if risk <7.5%, try lifestyle first for 3–6 mo, treat if still ≥130/80 (COR I, LOE B-R).
📝How effective is lifestyle modification in your practice? #NephJC
2️⃣Risk-based treatment threshold – Use PREVENT 10-yr CVD risk ≥7.5% to guide drug initiation at ≥130/80; if risk <7.5%, try lifestyle first for 3–6 mo, treat if still ≥130/80 (COR I, LOE B-R).
📝How effective is lifestyle modification in your practice? #NephJC
September 17, 2025 at 1:41 AM
T4b
2️⃣Risk-based treatment threshold – Use PREVENT 10-yr CVD risk ≥7.5% to guide drug initiation at ≥130/80; if risk <7.5%, try lifestyle first for 3–6 mo, treat if still ≥130/80 (COR I, LOE B-R).
📝How effective is lifestyle modification in your practice? #NephJC
2️⃣Risk-based treatment threshold – Use PREVENT 10-yr CVD risk ≥7.5% to guide drug initiation at ≥130/80; if risk <7.5%, try lifestyle first for 3–6 mo, treat if still ≥130/80 (COR I, LOE B-R).
📝How effective is lifestyle modification in your practice? #NephJC